Closeup view of an aircraft preparing to take off
Our Work

Latham Advises Invetx in its US$60.5 Million Series B Financing

May 10, 2022
A Boston-based team advises on the oversubscribed funding round.

Invetx, a pioneer in protein-based therapeutics for animal health, has announced that it has raised US$60.5 million in an oversubscribed Series B financing. The investment was led by F-Prime Capital, Novo Holdings, GV (formerly Google Ventures) and Eight Roads, with participation from existing investors Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. The proceeds allow the company to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats.

Latham & Watkins advised Invetx on its financing round with a corporate deal team led by Boston partners Spencer Ricks and Kristen Grannis, with associates Peter Prial and Andrew Rondeau.

Endnotes

    Contacts

    Ricks, Spencer B.

    Spencer B. Ricks

    Boston
    spencer.ricks@lw.com +1.617.880.4524
    Grannis, Kristen Smith

    Kristen Smith Grannis

    Boston / New York
    kristen.grannis@lw.com +1.617.948.6056